US 12,226,408 B2
Co-crystals
Daniel G. Chain, New York, NY (US); and Ronald Mueller, Northbrook, IL (US)
Assigned to CereSpir Incorporated, New York, NY (US)
Filed by CereSpir Incorporated, New York, NY (US)
Filed on Aug. 29, 2022, as Appl. No. 17/897,388.
Claims priority of provisional application 63/238,928, filed on Aug. 31, 2021.
Prior Publication US 2023/0113097 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/455 (2006.01); A61K 31/192 (2006.01)
CPC A61K 31/455 (2013.01) [A61K 31/192 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A pharmaceutical formulation comprising a therapeutically effective amount of an AICD inhibitor, the AICD inhibitor being in a form of a co-crystal, the co-crystal comprising a crystal lattice comprising molecules of the AICD inhibitor and a coformer, the AICD inhibitor interacting nonionically with the coformer in the crystal lattice, the AICD inhibitor and the coformer being associated only by non-ionic and noncovalent bonds, wherein
the coformer is not a solvent,
the pharmaceutical formulation consists of the AICD inhibitor, the coformer, the crystal lattice, and an optional pharmaceutically acceptable excipient(s),
the AICD inhibitor is itanapraced, and
the coformer is selected from a group consisting of citric acid, nicotinamide, saccharin, and vanillin.